Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Schweizer

Showing results (191-200 of 267) with videos related to

Pageof 27
Sort By:
Connecticut Medicine|July 1, 1996
Organ transplantation at the Hartford Transplant CenterR T Schweizer, S A Bartus, D Hull, et al.
Clinical Genitourinary Cancer|March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate CancerEmerson A Lim, Michael T Schweizer, Kim N Chi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2024
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, et al.
Plos One|June 2, 2018
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Plos One|August 16, 2018
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Oncotarget|October 21, 2016
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostateMichael T Schweizer, Heather H Cheng, Maria S Tretiakova, et al.
Science Translational Medicine|January 9, 2015
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical studyMichael T Schweizer, Emmanuel S Antonarakis, Hao Wang, et al.
The Journal of Urology|January 9, 2023
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical TrialMichael T Schweizer, Lawrence True, Roman Gulati, et al.
The Journal of Urology|January 9, 2023
Reply by AuthorsMichael T Schweizer, Lawrence True, Roman Gulati, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Pageof 27

Showing results (191-200 of 267) with videos related to

Sort By:
Pageof 27
Connecticut Medicine|July 1, 1996
Organ transplantation at the Hartford Transplant CenterR T Schweizer, S A Bartus, D Hull, et al.
Clinical Genitourinary Cancer|March 22, 2023
Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate CancerEmerson A Lim, Michael T Schweizer, Kim N Chi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 7, 2024
SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving <sup>177</sup>Lu-PSMA-617Ridvan Arda Demirci, Roman Gulati, Jessica E Hawley, et al.
Plos One|June 2, 2018
A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Plos One|August 16, 2018
Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancerMichael T Schweizer, Kathleen Haugk, Jožefa S McKiernan, et al.
Oncotarget|October 21, 2016
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostateMichael T Schweizer, Heather H Cheng, Maria S Tretiakova, et al.
Science Translational Medicine|January 9, 2015
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical studyMichael T Schweizer, Emmanuel S Antonarakis, Hao Wang, et al.
The Journal of Urology|January 9, 2023
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical TrialMichael T Schweizer, Lawrence True, Roman Gulati, et al.
The Journal of Urology|January 9, 2023
Reply by AuthorsMichael T Schweizer, Lawrence True, Roman Gulati, et al.
JCO Precision Oncology|January 9, 2023
Internet-Based Germline Genetic Testing for Men With Metastatic Prostate CancerHeather H Cheng, Alexandra O Sokolova, Roman Gulati, et al.
Pageof 27